BioMed Nexus

Stay on the Cutting Edge of Biotech, MedTech, and Pharma.

100% free, unsubscribe anytime.

LATEST ISSUES

Bicycle Shelves Padcev Challenger • Aldeyra's 3rd CRL • Jensen Huang's $1T Flex

Bicycle Shelves Padcev Challenger • Aldeyra's 3rd CRL • Jensen Huang's $1T Flex

Rhythm's PDUFA lands Friday, Lilly's obesity pill decision looms, and GTC puts pharma AI under the microscope.

Pharma’s GPU Arms Race Accelerates: Roche vs. Lilly at GTC

Pharma’s GPU Arms Race Accelerates: Roche vs. Lilly at GTC

ACIP meets Wednesday, Rhythm’s PDUFA lands Friday, and China clears the first commercial BCI.

Lilly Flags GLP-1 Impurity • Hims Exits Compounding • Sana Durability

Lilly Flags GLP-1 Impurity • Hims Exits Compounding • Sana Durability

Sana validates the T1D cure thesis at 14 months, ACIP meets Wednesday, and Rhythm's PDUFA lands Friday.

Lilly's Compounding Crackdown • Ultragenyx Hits Ph3 • Novo's Asset Slide

Lilly's Compounding Crackdown • Ultragenyx Hits Ph3 • Novo's Asset Slide

A new tirzepatide-B12 impurity escalates the GLP-1 compounding war as Pfizer winds down its biotech incubator.

BridgeBio’s LGMD Breakthrough • Stryker Cyberattack • Vima Adds $40M

BridgeBio’s LGMD Breakthrough • Stryker Cyberattack • Vima Adds $40M

FORTIFY Phase 3 data positions BBP-418 as the first LGMD therapy while Evotec cuts 800 jobs and CAR-T competition intensifies.

FDA Sets “Trial-Free” Precedent for Ultra-Rare Disease • BioNTech Founders Pivot • Hims Lands Ozempic

FDA Sets “Trial-Free” Precedent for Ultra-Rare Disease • BioNTech Founders Pivot • Hims Lands Ozempic

Leucovorin approved using literature evidence alone as BioNTech shares drop and GLP-1 telehealth tensions ease.